Jibril Rajoub attended opening match in Mexico but becomes latest football official hit by US visa issues, he says The head of the Palestinian Football Association has said he is unable to travel to the United States with other federation heads attending the 2026 Fifa World Cup because he has not been issued a visa. Jibril Rajoub went to the opening match between Mexico and South Africa in Mexico ...
Jibril Rajoub attended opening match in Mexico but becomes latest football official hit by US visa issues, he says The head of the Palestinian Football Association has said he is unable to travel to the United States with other federation heads attending the 2026 Fifa World Cup because he has not been issued a visa. Jibril Rajoub went to the opening match between Mexico and South Africa in Mexico City on Thursday. But he is among several people accredited to attend the World Cup who have been denied visas or have yet to receive them from the United States. Continue reading...
Over the last 7 days, the United States market has experienced a 2.4% drop, although it remains up by 22% over the past year, with earnings projected to grow by 18% annually in the coming years. In this environment, companies that exhibit both strong growth potential and high insider ownership can be particularly appealing as they often indicate confidence from those who know the business best.
Over the last 7 days, the United States market has experienced a 2.4% drop, although it remains up by 22% over the past year, with earnings projected to grow by 18% annually in the coming years. In this environment, companies that exhibit both strong growth potential and high insider ownership can be particularly appealing as they often indicate confidence from those who know the business best.
The death crosses flashing on both Hershey (NYSE: HSY) and Vertex Pharmaceuticals (NASDAQ: VRTX) are a bearish technical signal that Wall Street is openly ignoring. Analyst consensus on both stocks is solidly bullish, with double-digit implied upside to consensus targets, and the institutional bid keeps appearing even as the 50-day moving averages drift below the ... The Death Cross Is Lying: Why ...
The death crosses flashing on both Hershey (NYSE: HSY) and Vertex Pharmaceuticals (NASDAQ: VRTX) are a bearish technical signal that Wall Street is openly ignoring. Analyst consensus on both stocks is solidly bullish, with double-digit implied upside to consensus targets, and the institutional bid keeps appearing even as the 50-day moving averages drift below the ... The Death Cross Is Lying: Why Wall Street Is Still Loading Up on Hershey and Vertex
Hut 8 ( HUT ) has appointed E. Stanley O'Neal as chair of the board of directors, effective immediately. O'Neal, an independent director of the company since November 2023, succeeds founding chair William Tai, who will continue to serve as a director and as a member of the nominating and governance committee. More on Hut 8 Mining You're Up 160% On Hut 8 Corp. -- Here's Why I'm Buying This Dip Agai...
Hut 8 ( HUT ) has appointed E. Stanley O'Neal as chair of the board of directors, effective immediately. O'Neal, an independent director of the company since November 2023, succeeds founding chair William Tai, who will continue to serve as a director and as a member of the nominating and governance committee. More on Hut 8 Mining You're Up 160% On Hut 8 Corp. -- Here's Why I'm Buying This Dip Again Hut 8: Richly Valued And Still Highly Dependent On Bitcoin Mining Why Hut 8's AI Infrastructure Pivot Is Still Undervalued Crypto stocks in focus as Bitcoin steadies after deep selloff Hut 8 unit prices $4.25B senior secured notes
Mesut Dogan/iStock Editorial via Getty Images Shares of Oracle ( ORCL ) continue to display above-average volatility, with shares selling off in reaction to the fourth quarter results being released, which in all honesty came in response to the strong momentum seen lately. I last reviewed shares in March, when the third quarter results were released, as a $160 stock at that time has risen to a hig...
Mesut Dogan/iStock Editorial via Getty Images Shares of Oracle ( ORCL ) continue to display above-average volatility, with shares selling off in reaction to the fourth quarter results being released, which in all honesty came in response to the strong momentum seen lately. I last reviewed shares in March, when the third quarter results were released, as a $160 stock at that time has risen to a high around $250 early in June. Shares are down 30% in just about ten days, to current levels around $175 per share, as frankly the setback comes a bit unexpectedly to me after a solid print, although with continued and more spending to come. A Reasonable End To 2026 Oracle announced a 21% increase in fourth quarter sales for its fiscal year 2026, with growth reported a point lower in constant currency terms, reported at $19.2 billion. This is driven by the cloud business, which grew sales in constant currency terms by 46% to $9.9 billion, now making up over half of sales. Cloud infra revenues of $5.8 billion were up 92% in constant currency terms, with Cloud apps revenues up just 9% to $4.1 billion. This spectacular growth offsets 3% revenue declines in the important $6.8 billion software segment and slower growth in the smaller hardware and services segment. GAAP operating earnings rose by 18% in constant currency terms, up about a billion in dollar terms to $6.1 billion, for margins equal to 32% of sales. Restructuring costs roughly increased a factor of 10 times to just over $800 million, these being a real headwind to earnings. This was even as amortization charges were down slightly in dollar terms. Such improvements are welcome as the spending boom made the interest bill jump to over $1.4 billion with net income to investors reported at $4.2 billion, posted at $1.45 per share, still up twenty-six cents on the year before. Adjusted earnings rose as much as $0.41 per share to $2.11 per share, but this number, among others, adjusted for $1.2 billion in stock-based compensa...
Mesut Dogan/iStock Editorial via Getty Images Shares of Oracle ( ORCL ) continue to display above-average volatility, with shares selling off in reaction to the fourth quarter results being released, which in all honesty came in response to the strong momentum seen lately. I last reviewed shares in March, when the third quarter results were released, as a $160 stock at that time has risen to a hig...
Mesut Dogan/iStock Editorial via Getty Images Shares of Oracle ( ORCL ) continue to display above-average volatility, with shares selling off in reaction to the fourth quarter results being released, which in all honesty came in response to the strong momentum seen lately. I last reviewed shares in March, when the third quarter results were released, as a $160 stock at that time has risen to a high around $250 early in June. Shares are down 30% in just about ten days, to current levels around $175 per share, as frankly the setback comes a bit unexpectedly to me after a solid print, although with continued and more spending to come. A Reasonable End To 2026 Oracle announced a 21% increase in fourth quarter sales for its fiscal year 2026, with growth reported a point lower in constant currency terms, reported at $19.2 billion. This is driven by the cloud business, which grew sales in constant currency terms by 46% to $9.9 billion, now making up over half of sales. Cloud infra revenues of $5.8 billion were up 92% in constant currency terms, with Cloud apps revenues up just 9% to $4.1 billion. This spectacular growth offsets 3% revenue declines in the important $6.8 billion software segment and slower growth in the smaller hardware and services segment. GAAP operating earnings rose by 18% in constant currency terms, up about a billion in dollar terms to $6.1 billion, for margins equal to 32% of sales. Restructuring costs roughly increased a factor of 10 times to just over $800 million, these being a real headwind to earnings. This was even as amortization charges were down slightly in dollar terms. Such improvements are welcome as the spending boom made the interest bill jump to over $1.4 billion with net income to investors reported at $4.2 billion, posted at $1.45 per share, still up twenty-six cents on the year before. Adjusted earnings rose as much as $0.41 per share to $2.11 per share, but this number, among others, adjusted for $1.2 billion in stock-based compensa...
(RTTNews) - Expensify, Inc. (EXFY), an expense management software company, on Friday announced the final results of its modified Dutch auction tender offer to purchase up to $25 million of its Class A common stock.
(RTTNews) - Expensify, Inc. (EXFY), an expense management software company, on Friday announced the final results of its modified Dutch auction tender offer to purchase up to $25 million of its Class A common stock.
Miivo Holdings ( MIVO:CA ) proposed a name change to Miivo AI subject to approval from the TSX Venture Exchange. The board approved the change on May 8, 2026 under the company’s governing corporate framework. "We have been focused on building AI-powered solutions for SMEs — and this name change ensures our corporate identity aligns with that mission. Artificial intelligence is not a feature of our...
Miivo Holdings ( MIVO:CA ) proposed a name change to Miivo AI subject to approval from the TSX Venture Exchange. The board approved the change on May 8, 2026 under the company’s governing corporate framework. "We have been focused on building AI-powered solutions for SMEs — and this name change ensures our corporate identity aligns with that mission. Artificial intelligence is not a feature of our business; it is the foundation of it." said Alexander Damouni, CEO. The company's trading symbol "MIVO" is expected to remain unchanged, subject to TSXV approval. More on Miivo Holdings Corp. Financial information for Miivo Holdings Corp.
Oddity Finance LLC, a wholly-owned indirect subsidiary of digital beauty and wellness company ODDITY Tech Ltd. ( ODD ), has entered into separate, privately negotiated repurchase agreements to buy back $50M in aggregate principal amount of its 0% exchangeable senior notes due 2030. The repurchases are expected to close on June 17, 2026 for an aggregate purchase price of $35M subject to customary c...
Oddity Finance LLC, a wholly-owned indirect subsidiary of digital beauty and wellness company ODDITY Tech Ltd. ( ODD ), has entered into separate, privately negotiated repurchase agreements to buy back $50M in aggregate principal amount of its 0% exchangeable senior notes due 2030. The repurchases are expected to close on June 17, 2026 for an aggregate purchase price of $35M subject to customary closing conditions. Following the completion of this deal, $550 million in aggregate principal amount of these specific senior notes will remain outstanding. Shares of ODDITY Tech held relatively flat following the announcement, closing down a minor 0.09% at $10.96. More on Oddity Tech Oddity Tech Ltd. (ODD) Q1 2026 Earnings Call Transcript Oddity Tech Ltd. 2026 Q1 - Results - Earnings Call Presentation Oddity Tech: Cheap, But The Ad Fix Still Has To Show Up These 10 small-cap consumer discretionary stocks are the least attractively valued based on valuation grades These 10 mid-cap consumer discretionary stocks are the least attractively valued based on valuation grades
Sakorn Sukkasemsakorn Rocket Pharmaceuticals ( RCKT ) on Friday disclosed more than $320M in cash, cash equivalents, and investments pro forma after completing the previously disclosed sale of its rare pediatric disease priority review voucher. In April, the company announced $180M in potential gross proceeds after agreeing to sell the PRV, which it received following FDA approval of its gene ther...
Sakorn Sukkasemsakorn Rocket Pharmaceuticals ( RCKT ) on Friday disclosed more than $320M in cash, cash equivalents, and investments pro forma after completing the previously disclosed sale of its rare pediatric disease priority review voucher. In April, the company announced $180M in potential gross proceeds after agreeing to sell the PRV, which it received following FDA approval of its gene therapy, Kresladi, for a rare immune disease called leukocyte adhesion deficiency-I earlier this year. On Friday, the Cranbury, New Jersey-based biotech said it has completed the sale, and as a result, its cash, cash equivalents, and investments, which stood at $144.4M as of March 31, will rise to roughly $322.6M. The non-dilutive capital from the PRV sale will help it extend its cash runway through Q2 2028, the company added. More on Rocket Pharmaceuticals Rocket Pharmaceuticals, Inc. (RCKT) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript Rocket Pharmaceuticals, Inc. (RCKT) Presents at Jefferies Global Healthcare Conference 2026 Transcript Rocket Pharmaceuticals: Kresladi Approval Validates Platform, But Commercial Upside Remains Limited Rocket Pharma wins FDA nod for gene therapy (update) Seeking Alpha’s Quant Rating on Rocket Pharmaceuticals
Investing.com -- Citi has upgraded Advanced Micro Devices to Buy from Neutral, raising its price target to $575 from $460, arguing that the company's emergence as a "legit second source in the GPU market" is not yet reflected in the stock price.
Investing.com -- Citi has upgraded Advanced Micro Devices to Buy from Neutral, raising its price target to $575 from $460, arguing that the company's emergence as a "legit second source in the GPU market" is not yet reflected in the stock price.
Riya Mahesh is the ‘insanely Texas girl’ and medical student whose music splits the difference between dazed ambient production and big-tent pop melody From Boston, via Texas Recommended if you like Grace Ives, Porter Robinson, Grimes Up next Touring EU/UK in November Riya Mahesh has perfected her own sweet, whimsical brand of plunderphonics; her seventh project as Quiet Light in six years, this y...
Riya Mahesh is the ‘insanely Texas girl’ and medical student whose music splits the difference between dazed ambient production and big-tent pop melody From Boston, via Texas Recommended if you like Grace Ives, Porter Robinson, Grimes Up next Touring EU/UK in November Riya Mahesh has perfected her own sweet, whimsical brand of plunderphonics; her seventh project as Quiet Light in six years, this year’s Blue Angel Sparkling Silver 2, sounds a little as if it’s been chopped together from samples of Mahesh’s own memory. On Berlin, she sings to a wayward love interest over a moony breakbeat and IDM glitches, as a spoken-word part – what sounds to me like a recording of a lecture – floats in the background. Star100 starts all whispers and garbled laughter, before ceding space to Mahesh’s multitracked harmonies. Sometimes, Mahesh will suddenly deliver a wildly catchy chorus, something she clearly has an aptitude for – check Dealerz, her collab with Danish band A Good Year. Continue reading...
While La Calera faced severe water rationing, local springs were being drained by the drinks giant’s franchise. So the residents fought back When a severe drought struck La Calera near Bogotá, many of its residents lost their water for drinking, cooking and farming and faced up to 15 days of strict water rationing each month. Yet the area is home to Chingaza reservoir, which supplies about 70% of ...
While La Calera faced severe water rationing, local springs were being drained by the drinks giant’s franchise. So the residents fought back When a severe drought struck La Calera near Bogotá, many of its residents lost their water for drinking, cooking and farming and faced up to 15 days of strict water rationing each month. Yet the area is home to Chingaza reservoir, which supplies about 70% of the drinking water for Colombia ’s capital. As the drought stretched from April 2024 to April last year, people began to look more closely at how their water was being managed. Continue reading...
Nearly a month into the Ebola outbreak in the Democratic Republic of the Congo, cases continue to rise as officials are still trailing the virus in their response efforts. As of Thursday, June 11, the DRC has reported 676 confirmed cases, 136 deaths, and 119 suspected cases. Uganda is reporting 19 confirmed cases and two deaths. The outbreak, caused by the Bundibugyo strain of Ebolavirus , is alre...
Nearly a month into the Ebola outbreak in the Democratic Republic of the Congo, cases continue to rise as officials are still trailing the virus in their response efforts. As of Thursday, June 11, the DRC has reported 676 confirmed cases, 136 deaths, and 119 suspected cases. Uganda is reporting 19 confirmed cases and two deaths. The outbreak, caused by the Bundibugyo strain of Ebolavirus , is already the third largest Ebola outbreak on record. But health experts fear that it could grow much larger and had been quietly spreading for months before the outbreak was declared on May 15. Read full article Comments